Pure Global
NCT05736861

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Susanna Naggie, MD·Phase 3·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Covid19
Drug/Device/Intervention
Ivermectin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Susanna Naggie, MD
Funder
Duke University
Location
Gilbert,Mesa,Peoria,Newport Beach,North Hollywood,Palo Alto,Colorado Springs,Colorado Springs,Stamford,Washington,Gainesville,Gainesville,Jacksonville,Jacksonville,Lake Mary,Lakeland,Miami,Miami,Miami, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Jun 08, 2021
End date
May 16, 2022
Enrollment
1800 participants
Primary outcome

Time to Sustained Recovery in Days

Summary

The purpose of this study is to evaluate the effectiveness of repurposed medications (study
 drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
 Participants will receive either study drug or placebo. They will self-report any new or
 worsening symptoms or medical events they may experience while taking study drug or placebo.
 This study is intended to be all remote with no in person visits, unless the study team feels
 it is in the best interest of a participant to see them in person.
 
 Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the
 activation of any new drug arms. This protocol was originally registered under NCT04885530.
 Per recent guidance on reporting master protocol research programs (MPRPs), a separate record
 for Arm A was created.

ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteRift Valley feverPlague
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05736861
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05736861 through Pure Global AI's free database. This Phase 3 trial is sponsored by Susanna Naggie, MD and is currently Completed. The study focuses on Covid19. Target enrollment is 1800 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.